ArticleDiscover oncology2025
Lactylation-related lncRNAs can forecast prognosis and immune response of lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) represents a significant proportion of lung cancer cases, with immunotherapy serving as a cornerstone of treatment. Although immunotherapy has advanced significantly, the prognosis for patients in advanced stages remains suboptimal. Lactylation, a newly discovered metabolic pathway, has been recognized as a critical mechanism driving the initiation and development of many cancers, including LUAD. Using machine learning, this research aims to pinpoint lactylation-related lncRNAs (LRLs) that could serve as prognostic markers in LUAD, shedding light on tumor development and novel therapeutic avenues.
resultsFour LRLs (AC090115.1, AC092718.4, AC092718.6, and AL451064.1) were incorporated into a prognostic model. This model successfully categorized patients into high-risk and low-risk groups, revealing differences in prognosis. Patients in the low-risk group demonstrated a better prognosis, while the other category showed aggressive tumor characteristics and reduced responses to immunotherapy.
conclusionsThis study developed an association between LRLs and outcomes in lung adenocarcinoma, suggesting that they can be used as a prognostic marker and therapeutic target. The observed differences in their expression between tumor and normal tissues further underline their significance in LUAD pathogenesis. By advancing the understanding of LUAD biology, this predictive model provides a novel platform for precision medicine, paving the way for personalized therapeutic strategies and improved prognostic accuracy for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.